Tuberous Sclerosis Complex: 3 Critical Approaches Compared
Why care is shifting from waiting for the first seizure toward EEG-guided prevention and molecular therapy in at-risk infants.
One-Minute Takeaway
- Tuberous sclerosis complex causes epilepsy in an estimated 70–90% of patients, usually starting in infancy; the strongest evidence below comes from randomized controlled trials.
- In the EPISTOP trial, EEG-guided preemptive vigabatrin lowered the odds of clinical seizures (OR 0.21) and drug-resistant epilepsy (OR 0.23) at 24 months.
- The PREVeNT trial reproduced fewer infantile spasms but found no benefit for cognition, focal seizures, or drug-resistant epilepsy at 24 months.
- Adjunctive everolimus (EXIST-3) achieved a ≥50% seizure reduction in 40.0% of high-exposure patients versus 15.1% on placebo.
- Evidence supports fewer infantile spasms and modest refractory-seizure control; it does not yet show a cognitive benefit from early treatment.
The Clinical Problem in Tuberous Sclerosis Complex
Tuberous sclerosis complex is a genetic disorder caused by loss-of-function variants in TSC1 or TSC2. That loss releases the mTOR signalling pathway from its normal brake, driving the cortical tubers and hyperexcitable networks that make epilepsy the most common neurological feature of the condition.
The same pathway explains why the disorder reaches beyond the brain. mTOR overactivation also drives benign tumours in the kidneys, heart, skin, and lungs, so tuberous sclerosis complex is a multisystem condition in which epilepsy is simply the most disabling early feature. In the developing brain, cortical tubers and abnormal cell signalling create networks primed to generate seizures within the first months of life.
Seizures usually begin in the first year of life. The early pattern is dominated by focal seizures and infantile spasms, and drug resistance often appears within months of onset rather than after years of treatment.
This early burden matters because seizures in infancy carry developmental and cognitive consequences, and earlier seizure control has been correlated with better neurodevelopmental outcomes. That link is the rationale for a proactive model: detect epileptogenesis early and intervene before, or immediately at, the first seizure.
Two features make timing central. Epileptiform changes on EEG often precede clinical seizures by weeks, opening a window in which the course of tuberous sclerosis complex might be altered. And because uncontrolled early seizures are associated with worse cognitive outcomes, waiting is not a neutral option.
Three strategies now define that model and organise this review — EEG surveillance to detect impending epilepsy, preemptive vigabatrin to intervene before clinical seizures, and mTOR inhibitors to target the underlying pathway directly.
Available Approaches in Tuberous Sclerosis Complex
The table below summarises the interventional evidence behind each strategy for tuberous sclerosis complex. It draws on three randomized controlled trials and two prospective studies, with every figure checked against its primary source. The sections that follow examine each approach in turn.
| Study / Trial | Design | N | Population | Intervention vs comparison | Key result |
|---|---|---|---|---|---|
| EPISTOP (Kotulska, 2021) | Multicenter RCT + open-label | 94 | TSC infants, no prior seizures, monthly video-EEG | Preemptive vigabatrin (at epileptiform EEG) vs conventional (at seizure onset) | At 24 mo (pooled): clinical seizures OR 0.21 (p=0.032); drug-resistant epilepsy OR 0.23 (p=0.022); no infantile spasms in the preemptive group (0% vs 40%, p<0.001) |
| PREVeNT (Bebin, 2024) | Phase IIb multicenter double-blind RCT | 56 randomized (84 enrolled) | TSC infants with epileptiform EEG, no prior seizures | Early vigabatrin vs placebo (until seizure onset) | Bayley-III cognition similar; no difference in epilepsy incidence, drug-resistant epilepsy, or time to first seizure at 24 mo; infantile spasms fewer and later |
| EXIST-3 (French, 2016) | Phase 3 double-blind RCT | 366 (119/117/130) | Age 2–65 y, TSC, treatment-resistant focal seizures | Adjunctive everolimus (low 3–7 or high 9–15 ng/mL) vs placebo | ≥50% seizure response: 40.0% high-exposure (95% CI 31.5–49.0), 28.2% low-exposure (95% CI 20.3–37.3) vs 15.1% placebo (95% CI 9.2–22.8) |
| Krueger (2013) | Prospective open-label phase I/II | 20 | TSC, medically refractory epilepsy | Adjunctive everolimus (single arm) | ≥50% seizure reduction in 12 of 20; overall median reduction 73% (p<0.001) |
| Overwater (2016) | Randomized cross-over RCT (open-label add-on) | 23 | Children 1.8–10.9 y, TSC, intractable epilepsy | Add-on sirolimus vs standard antiseizure therapy | Seizure frequency fell but without reaching significance (p=0.06); trial was underpowered to exclude a benefit |
EEG Surveillance
EEG surveillance is the detection layer of the proactive model. Serial video-EEG in infants can capture interictal epileptiform discharges that are strongly predictive of impending epilepsy, often before any clinical seizure is visible to the family.
International guidelines support a baseline EEG in infants with TSC, followed by an 8- to 24-hour video-EEG including sleep when the baseline is abnormal or nonspecific. Surveillance is not itself a treatment; its entire value lies in triggering timely intervention.
One caveat deserves emphasis. The monthly cadence used in the prevention trials has not been formally optimised in a randomized study, so the ideal interval remains a matter of expert judgement.
What surveillance detects is not background slowing but specific interictal epileptiform discharges. In infants with tuberous sclerosis complex, these discharges have proven strongly predictive of impending epilepsy, which is what gives serial monitoring its clinical logic.
Surveys of clinicians who manage tuberous sclerosis complex show that many centres already monitor infants with EEG and consider a preventive approach, though practice varies and the trial evidence is recent. The appeal is practical: a monitoring test carries little direct risk and converts an unpredictable wait into an actionable signal.
Preemptive Vigabatrin
Preemptive vigabatrin means starting the drug when epileptiform activity appears on EEG, before clinical seizures begin. An early open-label study by Jóźwiak and colleagues first suggested this could favourably alter the course of the epilepsy, and it set the stage for two randomized trials.
In that early work, infants who showed paroxysmal EEG activity before any clinical seizure were treated with vigabatrin. They reached better seizure control and cognitive scores at 24 months than infants treated only after seizures began. The signal was influential but came from a small, non-randomized cohort, which is exactly why the later trials were needed.
EPISTOP is the pivotal evidence. In this trial, preemptive treatment lowered the odds of clinical seizures (OR 0.21) and drug-resistant epilepsy (OR 0.23). No infant in the preemptive group developed infantile spasms, versus 40% in the conventional arm.
The timing effect was large. In the randomized arm, the median time to a first clinical seizure was 364 days with preventive treatment versus 124 days with conventional treatment. The open-label arm showed a similar gap, 426 versus 106 days. Preventive vigabatrin did not abolish epilepsy, but it delayed and softened it.
PREVeNT then tested the same concept against placebo in a fully blinded design. It reproduced the spasm benefit — fewer and later infantile spasms — but found no improvement in cognition, focal seizures, or drug-resistant epilepsy at 24 months. The two trials agree on spasms and diverge on seizure prevention.
The spasm finding carries particular weight. Infantile spasms in tuberous sclerosis complex often accompany a severely disorganised EEG and are linked to developmental regression, so preventing or delaying them is a worthwhile goal on its own. That both trials converged here makes the spasm result the most durable claim in the preemptive-vigabatrin evidence.
Guidelines describe rapid titration of vigabatrin to roughly 100–150 mg/kg/day. The drug carries a risk of retinal toxicity and of reversible MRI signal changes in infants, so vision and imaging surveillance accompany its use.
mTOR Inhibitors
mTOR inhibitors are the only approach that targets the causal mechanism of the disease. Because TSC arises from mTOR pathway overactivation, drugs that inhibit that pathway have a strong mechanistic rationale for both seizures and the tumours seen elsewhere in the body.
Everolimus has the best seizure evidence. In EXIST-3, adjunctive everolimus produced a clear, dose-dependent rise in the proportion of patients reaching at least a 50% fall in seizures, well above placebo. An earlier open-label study reported that 12 of 20 patients achieved at least a halving of their seizures.
The average effect followed the same gradient. The median reduction in seizure frequency reached 39.6% with high-exposure everolimus, compared with 14.9% on placebo. EXIST-3 spanned 25 countries, which strengthens confidence that the effect is real, even if it is moderate for most patients with tuberous sclerosis complex.
Sirolimus, a closely related agent, has weaker support. The Overwater randomized trial reduced seizure frequency but did not reach statistical significance (p=0.06) in only 23 children, and the authors noted the study was underpowered rather than clearly negative.
These benefits come with a cost. Everolimus commonly causes stomatitis, mouth ulceration, and infections, reflecting its antiproliferative action on mucosa. Serious adverse events occurred in 14% of everolimus-treated patients versus 3% on placebo, with higher-grade events more frequent at higher exposure.
The drug’s reach extends across the disease. Everolimus is also approved for two other tuberous sclerosis complex manifestations — subependymal giant cell astrocytomas that cannot be fully resected, and renal angiomyolipomas — where it reduces lesion volume. That breadth is unique among the options here and follows from its action on the root pathway rather than on seizures alone.
Whether mTOR inhibition can prevent rather than treat seizures is now being tested directly. TSC-STEPS is a placebo-controlled trial of early sirolimus in infants who have not yet developed seizures, and ViRAP compares sirolimus against vigabatrin for prevention. Until those results arrive, mTOR inhibitors remain a treatment for established seizures rather than a preventive tool.
Comparative Analysis
These three approaches answer different questions in tuberous sclerosis complex, and comparing them means being clear about which goal each one serves.
EEG surveillance is a diagnostic enabler rather than a therapy. Its worth is entirely downstream: it identifies the infant and the moment at which a preemptive drug can be started, and without it the preemptive strategy has no trigger.
Preemptive vigabatrin carries the most consistent signal for one specific outcome — infantile spasms — where both randomized trials agree. Its effect on preventing focal seizures and drug-resistant epilepsy is contested, positive in EPISTOP and null in PREVeNT, and neither trial showed a cognitive benefit at two years.
mTOR inhibition has the strongest biological rationale and a proven, if modest, effect on established refractory seizures, plus benefit for non-neurological TSC lesions. It also carries the heaviest adverse-event burden of the three and no confirmed role in prevention.
Timing may matter as much as the choice of drug. Human and laboratory data point to a developmental window in which mTOR-driven epileptogenesis in tuberous sclerosis complex is most modifiable. That is one reason preventive efforts concentrate on the first months of life, and why everolimus trials in older children show only moderate effects. The open question is whether starting a molecular therapy earlier could achieve what vigabatrin so far has not — a change in the cognitive trajectory.
Quality and Consistency of the Evidence
Strength of evidence varies sharply by outcome in tuberous sclerosis complex, and the honest picture is a mix of well-supported and unresolved claims.
- Moderate-to-high — reduction of infantile spasms by preemptive vigabatrin. Two randomized trials, EPISTOP and PREVeNT, independently show fewer and later spasms in treated infants.
- Moderate — everolimus for refractory focal-seizure reduction. One large phase 3 RCT with a dose-response gradient, supported by open-label and long-term follow-up data.
- Low / conflicting — preemptive vigabatrin for preventing focal seizures and drug-resistant epilepsy. EPISTOP was positive on these outcomes; PREVeNT was null.
- Insufficient — cognitive benefit from early treatment, and sirolimus for seizures. Cognition was unchanged in both vigabatrin trials, and the single sirolimus RCT was underpowered.
What the Evidence Does Not Show
Several important questions remain open, and naming them precisely matters more than a general call for further study.
Specific gaps in the current evidence:
- No demonstrated cognitive benefit from preemptive vigabatrin at 24 months in either randomized trial.
- No settled explanation for why EPISTOP and PREVeNT diverge on seizure and drug-resistant-epilepsy outcomes, given their different designs, populations, and placebo-arm crossover.
- No randomized definition of the optimal EEG surveillance interval in at-risk infants.
- Limited outcome data beyond 24 months for any of these strategies.
- No confirmed preventive role for mTOR inhibitors; infant trials of early sirolimus (TSC-STEPS) and sirolimus versus vigabatrin (ViRAP) are ongoing.
- Uncertainty about everolimus in the youngest infants, who were excluded from EXIST-3 (which enrolled from age 2 years), and about durability after withdrawal.
- No completed head-to-head comparison of vigabatrin against mTOR inhibition for prevention.
Practical Implications
The following reflect what the current evidence and guidelines support, framed as considerations rather than directives.
International guidance supports a baseline EEG and serial monitoring in infants diagnosed with TSC, so that epileptiform activity can be detected before clinical seizures. European recommendations go further, supporting introduction of vigabatrin as early as epileptiform EEG activity is recorded.
The international guideline frames preemptive vigabatrin as potentially delaying or preventing seizure onset in at-risk infants, while cautioning that it may not change the developmental trajectory. That nuance keeps expectations aligned with what the trials actually showed.
Everolimus is a regulatory-approved option for TSC-associated refractory focal seizures. Its use involves titration to a target trough level and a candid weighing of its adverse-event profile against the modest average seizure reduction.
Vigabatrin requires retinal and MRI vigilance during treatment. Across all of these choices, care is multidisciplinary, and epilepsy surgery is considered early in children whose seizures prove drug-resistant.
Shared decision-making matters because the evidence in tuberous sclerosis complex supports some goals more firmly than others. Families can be told that preventive vigabatrin is likely to reduce infantile spasms, that its effect on later seizures is uncertain, and that it has not been shown to improve cognition. That framing is one the trials themselves support.
Evidence Grade and Bottom Line
The evidence supports a genuine shift from reactive to proactive management for spasm prevention, but not, on current data, for changing cognitive outcomes.
The bottom line for clinicians weighing these approaches in tuberous sclerosis complex:
- EEG surveillance is the low-risk enabler that makes early intervention possible, though its ideal schedule is not yet defined by trial data.
- Preemptive vigabatrin is best supported for preventing infantile spasms; its effect on later seizures and cognition is unproven.
- Everolimus is a proven adjunct for refractory focal seizures and for TSC-related tumours, at the cost of a meaningful adverse-event burden.
- Match the strategy to the goal — spasm prevention, refractory-seizure control, or disease-wide tumour burden — rather than expecting any single approach to serve all three.
Article Information and References
- Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol. 2021;123:50-66. DOI: https://doi.org/10.1016/j.pediatrneurol.2021.07.011
- Specchio N, Nabbout R, Aronica E, et al. Updated clinical recommendations for the management of tuberous sclerosis complex associated epilepsy. Eur J Paediatr Neurol. 2023;47:25-34. DOI: https://doi.org/10.1016/j.ejpn.2023.08.005
- Kotulska K, Kwiatkowski DJ, Curatolo P, et al. Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial. Ann Neurol. 2021;89(2):304-314. DOI: https://doi.org/10.1002/ana.25956
- Bebin EM, Peters JM, Porter BE, et al. Early treatment with vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial. Ann Neurol. 2024;95(1):15-26. DOI: https://doi.org/10.1002/ana.26778
- French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153-2163. DOI: https://doi.org/10.1016/S0140-6736(16)31419-2
- Curatolo P, Franz DN, Lawson JA, et al. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. Lancet Child Adolesc Health. 2018;2(7):495-504. DOI: https://doi.org/10.1016/S2352-4642(18)30099-3
- Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74(5):679-687. DOI: https://doi.org/10.1002/ana.23960
- Krueger DA, Wilfong AA, Mays M, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology. 2016;87(23):2408-2415. DOI: https://doi.org/10.1212/WNL.0000000000003400
- Overwater IE, Rietman AB, Bindels-de Heus K, et al. Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial. Neurology. 2016;87(10):1011-1018. DOI: https://doi.org/10.1212/WNL.0000000000003077
- Jóźwiak S. Commentary regarding the results of the PREVeNT and EPISTOP trials. Ann Neurol. 2024. DOI: https://doi.org/10.1002/ana.26829